Answers are grounded in this paper and cite their sources.
Longitudinal analysis shows decreased myocardial T2 correlates with cardiotoxicity in breast cancer, indicating its utility for personalized treatment.
Motivation: To identify cancer therapy-related cardiac dysfunction (CTRCD) in patients with breast cancer (BC) receiving anthracycline Goal(s): To evaluate longitudinal changes in myocardial T2* and investigate the utility of T2* mapping for identifying CTRCD Approach: Seventy-eight participants with BC receiving anthracyclines were recruited. All participants underwent CMR at baseline, about 3 months and 6months. T2*, T1, T2 and strain were measured and compared. Logistic regression analysis and receiver operating characteristic analysis were used to assess the performance of T2* values in predicting CTRCD Results: T2* decreased, T1 and T2 increased in patients with BC receiving anthracyclines. T2* can predict subsequent CTRCD in these patients. Impact: Myocardial T2* mapping can identify subsequent CTRCD in patients with BC receiving anthracyclines with/without trastuzumab. This may facilitate accurate prediction of cardiotoxicity and personalized treatment decision making in breast cancer.
No takes yet. Share an insight, caveat, or question.
Tu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: